[go: up one dir, main page]

CN112915217A - Prostate cancer targeted prodrug and synthesis method thereof - Google Patents

Prostate cancer targeted prodrug and synthesis method thereof Download PDF

Info

Publication number
CN112915217A
CN112915217A CN202110126832.8A CN202110126832A CN112915217A CN 112915217 A CN112915217 A CN 112915217A CN 202110126832 A CN202110126832 A CN 202110126832A CN 112915217 A CN112915217 A CN 112915217A
Authority
CN
China
Prior art keywords
compound
prodrug
prostate cancer
synthesizing
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110126832.8A
Other languages
Chinese (zh)
Other versions
CN112915217B (en
Inventor
沈浪涛
周旭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atom High Tech Co ltd
Original Assignee
Atom High Tech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atom High Tech Co ltd filed Critical Atom High Tech Co ltd
Priority to CN202110126832.8A priority Critical patent/CN112915217B/en
Publication of CN112915217A publication Critical patent/CN112915217A/en
Application granted granted Critical
Publication of CN112915217B publication Critical patent/CN112915217B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention belongs to the technical field of cancer targeted drugs, and particularly relates to a precursor of a prostate cancer targeted metal drug and a synthesis method thereof, wherein the structural general formula of the metal drug precursor M is as follows:

Description

Prostate cancer targeted prodrug and synthesis method thereof
Technical Field
The invention belongs to the technical field of cancer targeted drugs, and particularly relates to a prostate cancer targeted prodrug and a synthesis method thereof.
Background
Prostate cancer is one of the malignant tumors that seriously threaten the health of men. The incidence of prostate cancer has increased in recent years and has become the fastest growing disease species among malignant tumors.
At present, the clinical diagnosis of the prostate cancer mainly depends on rectal digital examination, serum Prostate Specific Antigen (PSA), transrectal ultrasonic examination, Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and the like, and all the examination methods have certain values but also have defects and can not effectively carry out early diagnosis of the prostate cancer.
PET/CT (positron emission tomography) is one way of nuclear medicine imaging. It can reveal the condition of early disease occurrence and development at molecular or cellular level, and is a powerful means for early imaging diagnosis of prostate cancer and other tumors.
Positron-emitting radiopharmaceuticals have to be used in PET/CT imaging. The radioactive medicines for the PET/CT imaging diagnosis of the prostatic cancer mainly comprise C-11 labeled choline, F-18 labeled methyl choline and F-18 labeled fluciclovine. C-11 labeled choline is used for detection of primary prostate cancer, but it is difficult to distinguish prostate cancer from prostatitis or benign prostatic hypertrophy because of high uptake of the drug also in prostatitis or benign prostatic hypertrophy. F-18 labeled methyl or ethyl choline makes it difficult to diagnose locally recurrent prostate cancer. The sensitivity and specificity of diagnosing prostate cancer by F-18 labeled fluciclovine imaging are not high. In addition, these drugs require the use of the F-18 species, which can only be produced by expensive cyclotrons. After the F-18 nuclide is obtained, the F-18 labeled PET medicine needs to be synthesized, separated and purified by an automatic synthesizer which is not expensive and has complex operation. The entire process of F-18 labeling PET drugs is complex and time consuming. Therefore, there is a need for developing a non-F-18 labeled PET drug with better prostate cancer imaging diagnosis effect and easy production.
Ga-68 is usually composed of a non-expensive material68Ge/68Ga generator. The half-life of Ge-68 was about 271 days, so one was68Ge/68The Ga generator can stably supply Ga-68 nuclide for about 1 year, which provides great convenience for preparing various Ga-68 medicines at any time. The Ga-68-labeled PET medicine is prepared by the reaction of trivalent Ga-68 ions and coordination groups in the medicinePrepared by coordination reaction. The coordination reaction (i.e., radiolabelling) of Ga-68 ions with ligands is usually fast (complete in a matter of minutes-ten and several minutes) and high in labeling rate (generally greater than 90%, even almost quantitative), without additional isolation and purification of the drug. The synthesis process of the Ga-68 labeled PET medicine is simple and takes short time. Thus, is composed of68Ge/68The Ga-68 marked PET medicine generated by the Ga generator is beneficial to popularization and use and has wide application prospect.
Disclosure of Invention
In view of the above problems in the prior art, the present invention provides a class of prostate cancer-targeting prodrugs that form coordination compounds with gallium.
The structural general formula of the prodrug M is as follows:
Figure BDA0002924290930000021
Figure BDA0002924290930000031
the m is an integer of 2-5, the n is an integer of 1-9, and m at different positions can be the same or different.
The prostate specific membrane antigen PSMA (prostate specific membrane antigen) is overexpressed on the surface of all prostate cancer cells. It has been shown to have high sensitivity and specificity in the diagnosis of prostate cancer. The compound M can be specifically combined with a PSMA binding site on the cell surface, so that the targeted early diagnosis of the prostate cancer is realized; can also be chelated with a specific nuclide Ga, thereby achieving the purpose of tumor diagnosis or treatment.
Preferably, m is an integer of 2-5, and n is an integer of 1-5;
preferably, m is 3 and n is 2;
preferably, the synthetic route of the prodrug is as follows:
Figure BDA0002924290930000032
Figure BDA0002924290930000041
the synthesis of the compounds B and D comprises the following steps:
Figure BDA0002924290930000042
Figure BDA0002924290930000051
preferably, in the process of synthesizing the compound B from the compound A, the feeding mole number of the diamine compound is 1.4-1.8 times of that of the compound A;
in the reaction process, firstly adding a diamine compound, then adding NaOH, and finally adding a compound A;
preferably, in the process of synthesizing the compound C, nitromethane is added, the temperature is preheated to 65-70 ℃, Triton B is added, and tert-butyl acrylate is slowly added, and the reaction temperature is controlled not to exceed 80 ℃.
Preferably, in the process of synthesizing the compound H from the compound G, the feeding mole number of the compound B is more than 4 times of that of the compound G, and the reaction time is more than 3 days;
in the post-treatment process of the reaction, the silica gel used for column chromatography is 200-300 meshes, and the eluent comprises the following components: dichloromethane: methanol: triethylamine 5: 1: 0.05;
preferably, in the process of synthesizing the compound I from the compound H, adding a reactant and hydrazine hydrate into ethanol, and refluxing for 6-10H;
preferably, after the compound K is synthesized from the compound I and the compound J, the silica gel used for column chromatography in the post-treatment is 200-300 meshes, and the eluent comprises the following components: dichloromethane: methanol: triethylamine 5: 1: 0.05;
preferably, in the process of synthesizing the compound L from the compound K, a Pd/C catalyst is used, and the reaction is carried out for 2-4 days in the presence of hydrogen;
and in the process of synthesizing the compound M from the compound L, reacting for 1.5-2.5 h at room temperature by using trifluoroacetic acid.
Preferably, in the process of generating the compound F from the compound E, the compound H from the compound G, the compound J and the compound K from the compound I, the adopted active ester is any one or the combination of dicyclohexylcarbodiimide, 1-propylphosphoric anhydride, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, O-benzotriazole-tetramethylurea hexafluorophosphate, N-hydroxysuccinimide, 1-hydroxybenzotriazole and O-benzotriazol-N, N, N ', N' -tetramethylurea tetrafluoroboric acid.
The invention also protects the application of the prodrug in the preparation of early diagnosis drugs for prostate cancer.
Preferably, the prodrug is reacted with68Ga forms a coordination compound and is used for preparing early diagnosis drugs of prostate cancer.
The invention also protects the application of the prodrug in the preparation of a prostate cancer treatment drug.
The invention also protects the application of the prodrug of the invention in preparing a excretion-promoting medicament.
Preferably, in the preparation of promoted Al3+、Fe3+、Ac3+、Th4+And other radioactive lanthanide metal ions.
Preferably, the prodrug is introduced into the human body in combination with Al in the body3+、Fe3+、Ac3+、Th4+And other radioactive lanthanide series metal ions form coordination compounds to promote the discharge of the metal ions in human bodies and play a role in detoxification.
The invention has the following beneficial effects:
1) the compounds of the invention contain 3 functional groups of 2-methyl-3-hydroxy-4-pyridone, facilitating coordination to the metal ions of stable metal species such as trivalent gallium (Ga) and its radioisotope gallium-68/67/66, and all isotopes of trivalent iron (Fe), indium (In), bismuth (Bi), lutetium (Lu), yttrium (Y), scandium (Sc), samarium (Sm), terbium (Tb), gadolinium (Gd), actinium (Ac), aluminum (Al) and tetravalent thorium (Th), including stable isotopes and radioisotopes.
2) The compounds of the present invention contain 1 DUPA (Glu-urea-Glu: glutamic acid-urea-glutamic acid). Can be specifically and firmly combined with PSMA (prostate specific membrane antigen), thereby targeting prostate cancer.
3) The spacing of the compound DUPA fragments of the invention from the central backbone of the compound is separated by different chain lengths (n ═ 1, 2. This chain length can modulate the spacing between DUPA and the metal chelating group, affecting the degree of binding firmness of DUPA to PSMA and modulating the lipid solubility of the overall compound.
4) The spacing of the 2-methyl-3-hydroxy-4-pyridone functional group in the compounds of the invention from the central backbone of the compound is separated by different chain lengths (m ═ 2,3,4, 5). The chain length can adjust the coordination environment when 3 2-methyl-3-hydroxy-4-pyridone functional groups are coordinated with various metal ions with different ionic radii and adjust the fat solubility of the whole compound.
Drawings
FIG. 1 is a nuclear magnetic resonance hydrogen spectrum of a compound PSMA-GK;
FIG. 2 shows PSMA-GK and gallium nitrate (Ga (NO)3)3) Mass spectrum of the mixed solution (pH 6.5).
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Example 1
The compounds referred to in the examples are numbered as follows:
a compound A:
Figure BDA0002924290930000071
compound B:
Figure BDA0002924290930000072
compound C:
Figure BDA0002924290930000073
compound D:
Figure BDA0002924290930000081
compound E:
Figure BDA0002924290930000082
compound F:
Figure BDA0002924290930000083
compound G:
Figure BDA0002924290930000084
compound H:
Figure BDA0002924290930000091
a compound I:
Figure BDA0002924290930000092
compound J:
Figure BDA0002924290930000093
compound K:
Figure BDA0002924290930000101
a compound L:
Figure BDA0002924290930000102
compound M:
Figure BDA0002924290930000111
the compound is prepared by the following method:
a compound A: methyl maltol (20g) was used as a starting material, and methanol (100mL) was used as a solvent, and the starting material was dissolved by stirring. To the above solution was added dropwise a 7M NaOH solution (12.5 mL). After completion of the dropwise addition, benzyl chloride (13.2g) was added dropwise to the above solution, followed by refluxing overnight. The white solid formed in the reaction was removed by filtration, the solvent was removed by rotary evaporation, the crude product was dissolved in dichloromethane, washed three times with 5% NaOH solution and water, and the organic phase was dried over anhydrous sodium sulfate. The sodium sulfate was removed by filtration, the dichloromethane removed by rotary evaporation and the remaining oil dried in vacuo. Yield: 80 to 95 percent.
Compound B: (m-2, 3,4,5) in case of m-3: propylene diamine (1.7g) was used as a starting material, and was dissolved in a mixed solution of 10mL of ethanol and 20mL of deionized water, and 2M NaOH solution (2mL) was added to the solution. Compound A (5g) was dissolved in ethanol (10mL) and slowly dropped into the above solution using a constant pressure dropping funnel. The reaction was carried out at 60 ℃ overnight. Ethanol was removed by rotary evaporation and 50mL of water was added to the system. The pH was adjusted to 1 with 2M HCl and washed three times with DCM50mL leaving an aqueous phase. The aqueous phase was adjusted to pH 12 with 10M NaOH and extracted four times with DCM100 mL. The organic phases were combined and dried over sodium sulfate. The sodium sulfate was removed by filtration and the organic phase was spin-dried to give a brown yellow viscous oil. Yield: 50 to 70 percent.
Compound C: DME 20mL, nitromethane 6.1g, stirred in a round bottom flask. The temperature was monitored with a thermometer. The temperature was preheated to 65-70 degrees Celsius and 1mL of LTriton B (40% in MeOH) was added with no significant change in temperature. 39.7 g of tert-butyl acrylate were added in portions by syringe. And continuously dropwise adding tert-butyl acrylate until all the tert-butyl acrylate is completely dripped. When 13 g and 26 g of t-butyl acrylate were added dropwise, 1ml of Triton B was added. After all the solution is added, the reaction is carried out for 2 to 3 hours at a temperature of between 70 and 75 ℃. Return to room temperature and spin dry the solvent. The resulting solid was dissolved in 150mL of dichloromethane and washed with 50mL of 10% HCl and 3 × 50mL of saturated brine. Drying over sodium sulfate and spin-drying to remove dichloromethane afforded a large amount of a milky white solid. 90mL 95% ethanol. Yield: 40 to 80 percent.
Compound D: note that: the used aluminum-nickel alloy catalyst can be discarded after being diluted by a large amount of water and treated by dilute acid, and cannot be discarded at will.
100mL of absolute ethanol and 4.46g of compound C were added to the activated AlNiAl alloy catalyst (protected by absolute ethanol). Replacing nitrogen for three times; the hydrogen was replaced three more times. The reaction was carried out for 3 days at 60 ℃ using a hydrogen balloon. The aluminum nickel alloy is removed by the diatomite, and the diatomite is washed by ethanol until the filtrate is spotted on the plate and no product is spotted. The filtrates are combined and spin-dried. And (3) passing ethyl acetate through a column, performing spin drying after passing the ethyl acetate through the column to obtain colorless viscous oil, and standing at a low temperature to gradually solidify the oil to obtain a white solid. Yield: 85 to 100 percent.
Compound E: (n-2, 3,4, …,9) as an example n-2: 10g of phthalic anhydride, 6g of beta-aminopropionic acid and 66mL of acetic acid were added to a round-bottomed flask, and the mixture was refluxed for 4 hours. Spin-dry directly, wash with water to pH 7, and dry in vacuo. Yield: 86 to 95 percent.
Compound F: compound E (0.53g) and compound D (0.83g) were added to 15mL of dichloromethane in an ice bath. Anhydrous HOBT (0.31g), EDC (0.48g) was added. The reaction was warmed up overnight. And washing with deionized water for three times. Drying with sodium sulfate, removing solvent by rotary drying, and passing through a column. Eluent proportioning: ethyl acetate/petroleum ether (boiling range: 60-90 ℃) 1: 1. yield: 70 to 90 percent.
Compound G: compound F was dissolved in as little formic acid as possible and stirred overnight at room temperature. Spin-dry to give a white solid. Residual formic acid was removed in a vacuum drying oven. Yield: 90 to 100 percent.
Compound H: compound B (3.9G) and compound G (1.6G) were added to 15mL of N, N-dimethylformamide and cooled in an ice bath. Anhydrous HOBT (2.1g), EDC (3.0g) was added. The reaction was warmed up overnight. The solvent was removed by rotary evaporation, the remaining oil was dissolved in dichloromethane and washed three times with deionized water. Dried over sodium sulfate, rotary dried to remove dichloromethane, and passed through a column. Eluent proportioning: dichloromethane/methanol/triethylamine ═ 5: 1: 0.05. yield: 20 to 30 percent.
A compound I: compound H (900mg), dissolved in 20mL ethanol. To the above solution was added 900mg of hydrazine hydrate (purity 5% -50%) and refluxed for 3-8 hours. The system was cooled to 0 ℃, the pH was adjusted to 1 with concentrated hydrochloric acid, and the white solid was removed by filtration. The filtrate was spin-dried and the residue was dissolved in 30 ml of deionized water, adjusted to pH 12 with 10M sodium hydroxide solution and extracted three times with chloroform. The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the sodium sulfate and the organic phase was spin dried. Yield: 90 to 100 percent.
Compound J: l-glutamic acid di-tert-butyl ester hydrochloride (5g) was charged into a round-bottomed flask, and dissolved by adding 100mL of dichloromethane. Triethylamine (7.8mL) was added to the above solution and the system was cooled to-78 ℃. At this temperature, a solution of triphosgene (1.71g) in dichloromethane (10mL) was added to the system and the temperature was maintained at-78 ℃ for one hour. The system was returned to room temperature and held for one hour. The system was again cooled to-78 deg.C, and a solution of L-glutamic acid-5-benzyl ester-1-tert-butyl ester hydrochloride (6g) in dichloromethane (25mL) and triethylamine (5.7mL) were added thereto, and the mixture was allowed to react overnight at room temperature.
After the reaction, the system was quenched with 1M hydrochloric acid, the organic phase was separated with dichloromethane, dried over anhydrous sodium sulfate, filtered to remove sodium sulfate, and dichloromethane was spin-dried. And (5) passing through the column. Eluent polarity: ethyl acetate: petroleum ether is 1: 1.
the product is dissolved in dichloromethane, and 1-10% Pd/C catalyst is added. The system was purged with nitrogen three times and with hydrogen three times. The reaction was carried out under hydrogen conditions at room temperature for 24 hours.
After the reaction, the mixture was diluted with dichloromethane and passed through celite. Spin-drying to remove organic solvent, and passing through the column. Eluent polarity: petroleum ether: ethyl acetate 4: 6. and (4) recrystallizing petroleum ether/dichloromethane. Total yield: 60 to 90 percent.
Compound K: compound J (0.6g), Compound I (1.1g), was added to 15mL of N, N-dimethylformamide and cooled in ice. Anhydrous HOBT (160mg), EDC (240mg) was added. The reaction was warmed up overnight. The solvent was removed by rotary evaporation, the remaining oil was dissolved in dichloromethane and washed three times with deionized water. Dried over sodium sulfate, rotary dried to remove dichloromethane, and passed through a column. Eluent proportioning: dichloromethane/methanol/triethylamine ═ 5: 1: 0.05. yield: 20 to 80 percent.
A compound L: dissolving the compound K (100mg) in ethanol, and adding 1-10% of Pd/C catalyst. The system was purged with nitrogen three times and with hydrogen three times. The reaction was carried out under hydrogen conditions at room temperature for 24 hours. After the reaction, the mixture was diluted with ethanol and passed through celite. The organic solvent was removed by spin-drying.
Compound M: compound L (100mg) was dissolved in trifluoroacetic acid, reacted at room temperature for 3 hours, and the solvent was spin-dried.
Nuclear magnetic resonance hydrogen spectrum data and high-resolution mass spectrum data of the compound PSMA-GK (i.e., when n is 2 and M is 3 for the compound having the general formula M) are shown below. The hydrogen spectrum is shown in figure 1:
1H NMR(400MHz,DMSO-d6)δ1.72(m,CHCH2CH2COOH,2H),1.79-1.97(m,CONHCH2CH2CH2,CCH2CH2,CHCH2CH2CONH,14H),2.04(m,CCH2CH2,6H),2.12(m,CHCH2CH2COOH,2H),2.24(m,CONHCH2CH2,CHCH2CH2CONH,4H),2.50(s,CH3,9H),3.10(m,CONHCH2CH2CH2,6H),3.25(t,CONHCH2CH2,2H),4.06(m,CONHCHCOO,1H),4.11(m,CONHCHCOO,1H),4.31(t,CONHCH2CH2CH2,6H),6.40(t,Urea-H,2H),7.16(d,COCHCHN,3H),7.29(s,CONHC,1H),7.91(m,CONHCH2,1H),8.00(m,CONHCH2,3H),8.22(d,COCHCHN,3H).
HRMS M/z calculated 1113.5099(M + H)+Measured value of 1113.5094(M + H)+.
Example 2
The difference compared to example 1 is that the active ester used in the synthesis of compound F is DCC.
Example 3
The difference compared to example 1 is that the active ester used in the synthesis of compound H is EDC.
Example 4
The difference from example 1 is that the active ester used in the synthesis of compound K is HBTU.
Experimental example 1
The experiment takes a case that a prodrug compound PSMA-GK and a naturally-occurring trivalent ion of gallium (namely, a stable isotope of gallium without radioactivity) form a metal complex, and shows that the invented prodrug has the function of chelating metal ions such as gallium and the like.
The experimental method comprises the following steps:
adding gallium nitrate (Ga (NO)3)3) The solution was mixed with an aqueous solution of PSMA-GK (prepared in example 1) and then treated with a hydrochloric acid solution (0.1mol/l HCl) and sodium bicarbonate solution (1mol/l NaHCO)3) The pH of the mixture was adjusted to 6.5. The final concentration of the mixture was 0.022. mu. mol/l, and the mixture was left at room temperature.
The mass spectrum of the mixture was measured by time-of-flight mass spectrometry (MAIDI-TOF), and the results are shown in fig. 2.
The experimental results are as follows:
in the mass spectrum, a mass/charge ratio (m/z) of 1179.858 was observed, which is the most intense mass peak. The peak corresponds to the molecular formula C51H70N10O18M +1 peak of Ga compound. Compound C51H70N10O18Ga has a molecular weight of 1178.404, while its M +1 peak is calculated to be 1179.412, consistent with observations (1179.858). In addition, a mass spectrum peak at 1201.639 was observed, which corresponds to the molecular formula C51H69N10O18M + Na peak for compound of GaNa. Compound C51H69N10O18The molecular weight of GaNa was 1201.395, also consistent with observations (1201.639).
This indicates that 3 2-methyl-3-hydroxy-4-pyridone functional groups in the PSMA-GK compound are each dissociated into 1 hydrogen ion and Ga3+Effectively forming a metal complex of trivalent gallium. In the mixed solution, the formula is C51H70N10O18The complexes of Ga are the most predominant components.
Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that many modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims (10)

1. A class of prodrugs, wherein the structural formula of prodrug M is:
Figure FDA0002924290920000011
m is an integer of 2-5, and n is an integer of 1-9; wherein the value of m at different positions may be the same or different.
2. Prodrug M according to claim 1, characterized in that M is 3 and n is 2 in different positions.
3. A prodrug according to claim 1, wherein said prodrug is synthesized by the following route:
Figure FDA0002924290920000012
Figure FDA0002924290920000021
4. the method of synthesis according to claim 3, characterized in that the synthesis of compounds B and D comprises the following steps:
Figure FDA0002924290920000031
preferably, in the process of synthesizing the compound B from the compound A, the feeding mole number of the diamine compound is 1.4-1.8 times of that of the compound A;
in the reaction process, firstly adding a diamine compound, then adding NaOH, and finally adding a compound A;
and/or, in the process of synthesizing the compound C, adding nitromethane, preheating to 65-70 ℃, adding Triton B, then slowly adding tert-butyl acrylate, and controlling the reaction temperature to be not more than 80 ℃.
5. A synthesis method according to claim 3 or 4, characterized in that it comprises the following steps:
in the process of synthesizing the compound H from the compound G, the feeding mole number of the compound B is more than 4 times of that of the compound G, and the reaction time is more than 3 days;
in the post-treatment process of the reaction product, the silica gel used for column chromatography is 200-300 meshes, and the eluent comprises the following components: dichloromethane: methanol: triethylamine 5: 1: 0.05;
and/or adding a reactant and hydrazine hydrate into ethanol in the process of synthesizing the compound I from the compound H, and refluxing for 6-10H;
and/or after compound K is synthesized by the compound I and the compound J, the silica gel used for column chromatography in post-treatment is 200-300 meshes, and the eluent comprises the following components: dichloromethane: methanol: triethylamine 5: 1: 0.05;
and/or, in the process of synthesizing the compound L from the compound K, a Pd/C catalyst is used, and the reaction is carried out for 2-4 days in the presence of hydrogen;
and in the process of synthesizing the compound M from the compound L, reacting for 1.5-2.5 h at room temperature by using trifluoroacetic acid.
6. The synthesis method according to claim 3, wherein in the process of producing the compound F from the compound E, producing the compound H from the compound G, producing the compound K from the compound J and producing the compound K from the compound I, the adopted active ester is any one of dicyclohexylcarbodiimide, 1-propyl phosphoric anhydride, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, O-benzotriazole-tetramethylurea hexafluorophosphate, N-hydroxysuccinimide, 1-hydroxybenzotriazole, O-benzotriazole-N, N, N ', N' -tetramethylurea tetrafluoroborate or the combination thereof.
7. Use of a prodrug according to claim 1 or 2 for the preparation of a medicament for the early diagnosis of prostate cancer.
8. The use of claim 7, wherein the prodrug is conjugated to68Ga forms a coordination compound and is used for preparing early diagnosis drugs of prostate cancer.
9. Use of a prodrug as claimed in claim 1 or claim 2 in the manufacture of a medicament for the treatment of prostate cancer.
10. Use of a prodrug according to claim 1 or 2 for the preparation of an excretion-promoting drug, preferably, for the preparation of Al-promoting substances3+、Fe3+、Ac3+、Th4+And other radioactive lanthanide metal ions.
CN202110126832.8A 2021-01-29 2021-01-29 Prostate cancer targeted prodrug and synthesis method thereof Active CN112915217B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110126832.8A CN112915217B (en) 2021-01-29 2021-01-29 Prostate cancer targeted prodrug and synthesis method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110126832.8A CN112915217B (en) 2021-01-29 2021-01-29 Prostate cancer targeted prodrug and synthesis method thereof

Publications (2)

Publication Number Publication Date
CN112915217A true CN112915217A (en) 2021-06-08
CN112915217B CN112915217B (en) 2022-12-27

Family

ID=76168567

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110126832.8A Active CN112915217B (en) 2021-01-29 2021-01-29 Prostate cancer targeted prodrug and synthesis method thereof

Country Status (1)

Country Link
CN (1) CN112915217B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266359A (en) * 2017-07-12 2017-10-20 原子高科股份有限公司 A kind of chelating agent, its synthetic method and purposes and the chelate containing the chelating agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266359A (en) * 2017-07-12 2017-10-20 原子高科股份有限公司 A kind of chelating agent, its synthetic method and purposes and the chelate containing the chelating agent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRETT A. VAUGHN等: "Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44", 《CHEM. SCI.》 *
SUMITH A. KULARATNE等: "Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents", 《MOLECULAR PHARMACEUTICS》 *
VALERIA M. NURCHI等: "New strong extrafunctionalizable tris(3,4-HP) and bis(3,4-HP) metal sequestering agents: synthesis, solution and in vivo metal chelation", 《DALTON TRANS.》 *

Also Published As

Publication number Publication date
CN112915217B (en) 2022-12-27

Similar Documents

Publication Publication Date Title
JP6831834B2 (en) Method of preparing L-BPA
KR102688527B1 (en) Tumor diagnosis and treatment integrated boron delivery agent, manufacturing method and use thereof
JP6405573B2 (en) Method for producing 4-borono-L-phenylalanine having 18F atoms introduced and precursor of 4-borono-L-phenylalanine having 18F atoms introduced
CN112023064A (en) Tin-based derivative of fibroblast activation protein inhibitor for labeling nuclide 211At and preparation method and application thereof
CN108299482B (en) F-BPA and its intermediate synthesis method, intermediate and application
Telegina et al. Synthesis of a novel planar-chiral nido-carborane amino acid
CN112979684A (en) Preparation of18Process for F-BPA
CN109988187A (en) A kind of carborane-containing phenylalanine compound and its preparation method and use
CN112915217B (en) Prostate cancer targeted prodrug and synthesis method thereof
CN118344390A (en) Polyboronate substituted phenylalanine derivative and preparation method and application thereof
ES2746255T3 (en) Organotin reagents supported on ionic liquid for the manufacture of radiopharmaceuticals
CN110642861A (en) PET/CT tracer agent with selectivity on different lung cancer cells and preparation method and application thereof
CN108358958B (en) Intermediate, intermediate synthesis method and application
CN105348309B (en) F-BPA nucleophilic synthesis method
CA2591042A1 (en) Process for the preparation of a boron-substituted porphyrin
CN118994222A (en) Preparation method and application of intermediate of 4-boron-10 acid-L-phenylalanine
CN115368346B (en) 1, 4-benzodioxane-benzimidazole salt compound and synthesis method and application thereof
CN108409760A (en) Intermediate, intermediate synthetic method and application
CN102603555A (en) All-trans retinoic acid amide derivative and preparation method and application thereof
CA3150073C (en) New nucleophile-reactive sulfonated compounds for the (radio)labelling of (bio)molecules; precursors and conjugates thereof
CN113318227B (en) Boron-doped tumor targeting drug and preparation method and application thereof
WO2024021556A1 (en) Radioactive metal complex targeting prostate specific membrane antigen and labeling ligand thereof
Ahmad et al. Boron in my mind: A comprehensive review of the evolution and State-of-the-Art of the diverse syntheses of 4-borono-L-phenylalanine, the leading agent for boron neutron capture therapy
CN119118880A (en) A F-18 labeled PSMA inhibitor and its preparation method and application
CN114685599A (en) PSMA (patterned beam mosaic Virus inhibitor) targeted inhibitor, radionuclide-labeled PSMA targeted inhibitor, preparation method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant